CN111727254B - 使用突变型p53特异性siRNA进行癌症治疗性靶向 - Google Patents

使用突变型p53特异性siRNA进行癌症治疗性靶向 Download PDF

Info

Publication number
CN111727254B
CN111727254B CN201980013819.2A CN201980013819A CN111727254B CN 111727254 B CN111727254 B CN 111727254B CN 201980013819 A CN201980013819 A CN 201980013819A CN 111727254 B CN111727254 B CN 111727254B
Authority
CN
China
Prior art keywords
mutant
sirna
seq
double stranded
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201980013819.2A
Other languages
English (en)
Chinese (zh)
Other versions
CN111727254A (zh
Inventor
卡纳加·萨芭帕蒂
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Singapore Health Services Pte Ltd
Original Assignee
Singapore Health Services Pte Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Singapore Health Services Pte Ltd filed Critical Singapore Health Services Pte Ltd
Publication of CN111727254A publication Critical patent/CN111727254A/zh
Application granted granted Critical
Publication of CN111727254B publication Critical patent/CN111727254B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1135—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against oncogenes or tumor suppressor genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/31—Combination therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/34—Allele or polymorphism specific uses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/178—Oligonucleotides characterized by their use miRNA, siRNA or ncRNA

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Plant Pathology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
CN201980013819.2A 2018-02-21 2019-02-21 使用突变型p53特异性siRNA进行癌症治疗性靶向 Active CN111727254B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SG10201801432S 2018-02-21
SG10201801432S 2018-02-21
PCT/SG2019/050099 WO2019164451A1 (en) 2018-02-21 2019-02-21 Cancer therapeutic targeting using mutant p53-specific sirnas

Publications (2)

Publication Number Publication Date
CN111727254A CN111727254A (zh) 2020-09-29
CN111727254B true CN111727254B (zh) 2024-12-17

Family

ID=67687981

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980013819.2A Active CN111727254B (zh) 2018-02-21 2019-02-21 使用突变型p53特异性siRNA进行癌症治疗性靶向

Country Status (8)

Country Link
US (1) US12508277B2 (enExample)
EP (1) EP3755802A4 (enExample)
JP (3) JP2021514195A (enExample)
KR (1) KR102741498B1 (enExample)
CN (1) CN111727254B (enExample)
CA (1) CA3090220A1 (enExample)
SG (1) SG11202007450XA (enExample)
WO (1) WO2019164451A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3090220A1 (en) 2018-02-21 2019-08-29 Singapore Health Services Pte Ltd Cancer therapeutic targeting using mutant p53-specific sirnas
EP4077370A4 (en) * 2019-12-17 2024-02-28 The Johns Hopkins University MANA BODY TARGETING TUMOR ANTIGENS AND METHODS OF USE
CN115820636B (zh) * 2022-09-02 2024-06-11 华南农业大学 靶向TP53基因的sgRNA及其应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2832154B1 (fr) * 2001-11-09 2007-03-16 Centre Nat Rech Scient Oligonucleotides inhibiteurs et leur utilisation pour reprimer specifiquement un gene
CA3090220A1 (en) 2018-02-21 2019-08-29 Singapore Health Services Pte Ltd Cancer therapeutic targeting using mutant p53-specific sirnas

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Allele-specific silencing of mutant p53 attenuates dominant-negative and gain-of-function activities;Swathi V. Iyer;图1-5;第7卷(第5期);图1-5 *
Selective Inhibition of p53 Dominant Negative Mutation by shRNA Resulting in Partial Restoration of p53 Activity;Edmund I-Tsuen Chen;J Med Sci;第29卷(第4期);图1 *

Also Published As

Publication number Publication date
SG11202007450XA (en) 2020-09-29
JP7648675B2 (ja) 2025-03-18
EP3755802A1 (en) 2020-12-30
US12508277B2 (en) 2025-12-30
WO2019164451A8 (en) 2020-11-26
JP2021514195A (ja) 2021-06-10
CA3090220A1 (en) 2019-08-29
JP2023096009A (ja) 2023-07-06
CN111727254A (zh) 2020-09-29
WO2019164451A1 (en) 2019-08-29
KR20200123165A (ko) 2020-10-28
EP3755802A4 (en) 2021-11-17
US20200397813A1 (en) 2020-12-24
KR102741498B1 (ko) 2024-12-11
JP2025093992A (ja) 2025-06-24

Similar Documents

Publication Publication Date Title
Yang et al. Sp1-mediated microRNA-182 expression regulates lung cancer progression
AU2011325956B2 (en) Polycomb-associated non-coding RNAs
JP7648675B2 (ja) 変異Ｐ５３特異的ｓｉＲＮＡを使用した標的癌治療
ES2447868T3 (es) Inhibidores de la BTK para uso en el tratamiento de tumores epiteliales resistentes a fármacos quimioterapéuticos
US20200056177A1 (en) Long non-coding rna used for anticancer therapy
CN113633656A (zh) 包含微小核糖核酸作为活性成分的用于治疗癌症的药物组合物
US20150152422A1 (en) Mirnas as therapeutic targets in cancer
KR102547432B1 (ko) Tut4/7 발현 조절인자를 포함하는 암 예방 또는 치료용 약학적 조성물
JP2016064989A (ja) 癌を治療するための医薬組成物、およびｐｄ−１阻害剤による治療に対する感受性を評価する方法
US20120225076A1 (en) Fra-1 target genes as drug targets for treating cancer
EP2866822B1 (en) U1 snrnp regulates gene expression and modulates oncogenicity
WO2013131143A1 (en) Micrornas and uses thereof
US7999089B1 (en) RNA aptamers and the uses thereof
KR102737434B1 (ko) Tead4 억제제를 포함하는 대장암 예방 또는 치료용 약학 조성물
US11667919B2 (en) Targeting cancer-associated long non-coding RNAs
EP3946629A1 (en) Therapeutic targets for oncogenic kras-dependent cancers
JP2012171894A (ja) 腫瘍縮小剤
Vigevani Molecular mechanisms of alternative splicing regulation by antitumor drugs targeting U2 snRNP
CN105147714A (zh) 小分子RNA的应用及Rho激酶抑制剂
KR100986465B1 (ko) Ｏｉｐ５ 유전자의 신규한 용도
CN114081896A (zh) let-7i-3p在制备治疗结直肠癌的药物中的应用及方法

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant